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Abstract
Background: Creatine monohydrate (CrM) and nitrate are popular supplements for improving exercise
performance; yet have not been investigated in combination. We performed two studies to determine the safety
and exercise performance-characteristics of creatine nitrate (CrN) supplementation.
Methods: Study 1 participants (N = 13) ingested 1.5 g CrN (CrN-Low), 3 g CrN (CrN-High), 5 g CrM or a
placebo in a randomized, crossover study (7d washout) to determine supplement safety (hepatorenal and
muscle enzymes, heart rate, blood pressure and side effects) measured at time-0 (unsupplemented), 30-min,
and then hourly for 5-h post-ingestion. Study 2 participants (N = 48) received the same CrN treatments vs. 3 g
CrM in a randomized, double-blind, 28d trial inclusive of a 7-d interim testing period and loading sequence
(4 servings/d). Day-7 and d-28 measured Tendo™ bench press performance, Wingate testing and a 6x6-s
bicycle ergometer sprint. Data were analyzed using a GLM and results are reported as mean ± SD or mean
change ± 95 % CI.
Results: In both studies we observed several significant, yet stochastic changes in blood markers that were not
indicative of potential harm or consistent for any treatment group. Equally, all treatment groups reported a
similar number of minimal side effects. In Study 2, there was a significant increase in plasma nitrates for both CrN
groups by d-7, subsequently abating by d-28. Muscle creatine increased significantly by d-7 in the CrM and
CrN-High groups, but then decreased by d-28 for CrN-High. By d-28, there were significant increases in bench
press lifting volume (kg) for all groups (PLA, 126.6, 95 % CI 26.3, 226.8; CrM, 194.1, 95 % CI 89.0, 299.2; CrN-Low,
118.3, 95 % CI 26.1, 210.5; CrN-High, 267.2, 95 % CI 175.0, 359.4, kg). Only the CrN-High group was significantly
greater than PLA (p < 0.05). Similar findings were observed for bench press peak power (PLA, 59.0, 95 % CI 4.5,
113.4; CrM, 68.6, 95 % CI 11.4, 125.8; CrN-Low, 40.9, 95 % CI −9.2, 91.0; CrN-High, 60.9, 95 % CI 10.8, 111.1, W) and
average power.
Conclusions: Creatine nitrate delivered at 3 g was well-tolerated, demonstrated similar performance benefits to
3 g CrM, in addition, within the confines of this study, there were no safety concerns.
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Background
Numerous nutrition supplements have been investigated
to determine their ergogenic benefits related to exercise
performance. Two supplements that are currently popu-
lar in the marketplace are creatine and nitrate. Creatine
has been extensively researched and has been the subject
of numerous reviews and position statements attesting
to its efficacy and safety in sport and in health [5, 7, 8].
It has been well established that supplementation with
creatine can increase strength performance and improve
overall body anthropometry via a reduction in percent
body fat and increased fat-free mass [5]. Recently, diet-
ary nitrate ingestion has gained in popularity as a means
of improving endurance performance.
Inorganic nitrate (NO3
−) is an ion exhibiting limited
synthesis in the body, therefore usually obtained from
the diet via green leafy vegetables, while nitrites (NO2
−)
are also found in food as processing additives, but to a
much lesser degree [13]. The ingestion of nitrate have
demonstrated its importance to health in that nitrate
and nitrite can be reduced to nitric oxide, which has
shown to have numerous physiologic effects in exercise
and health [16, 17, 19]. While extensive reviews are
available elsewhere, nitrate ingestion has been shown to
reduce the oxygen cost of exercise and improve exercise
tolerance [22, 24]. For example, Larsen et al., reported a
reduction in maximal oxygen consumption; yet a trend
for improvement in time-to-exhaustion accompanying
the ingestion of sodium nitrate intake at 0.1 mmol/kg/
day for three days [22]. In a similar study by the same
group, investigators reported a significant reduction in
oxygen consumption and improvement in gross effi-
ciency at sub-maximal workloads using the same inges-
tion schema [24]. Bescos et al., (2011) investigated the
impact of sodium nitrate in highly trained cyclist and tri-
athletes and found that the consumption of 10 mg/kg
prior to a cycle ergometer test reduced VO2peak without
influencing time to exhaustion or maximal power output
[3]. Further research has elaborated on these findings,
showing a reduction in the amplitude of the VO2 slow
component; hence an improvement in muscle efficiency
associated with nitrate ingestion [2, 18].
Despite the number of studies associated with endur-
ance performance, a dearth of literature exists examining
nitrate supplementation on strength performance; and
no studies that we are aware of have examined the role
of creatine and nitrate in combination. However, the two
nutrients have the potential to work synergistically. The
primary aim of our current study was to examine the ef-
fects of creatine nitrate (CrN) in a two-phase, dose
dependent study administering CrN at 1.5 g (CrN-Low)
and 3 g (CrN-High). Study 1 of our trial examined the
acute ingestion of the respective treatments for five
hours following ingestion. Study 2 of our trial examined
each respective treatment for 28 days. Each CrN condi-
tion was compared to a placebo (PLA) and creatine
monohydrate (CrM) treatment condition. We hypothe-
sized that CrN would increase exercise performance and
related performance indices (e.g., peak power, mean
power, total work, etc.) in a dose dependent manner and
be equal in effectiveness to CrM. We further hypothe-
sized that CrN ingestion would not adversely affect
hepatorenal function or hemodynamics indices following
acute and chronic ingestion.
Methods
The current report represents studies examining the [1]
acute and [2] chronic supplementation of a CrN for-
mula. Study 1 was an acute phase study with partici-
pants ingesting each respective supplement one time in
a randomized, double blind, crossover manner. Study 2
was a 28-d study using different participants receiving
treatments in a randomized, double blind manner.
Figure 1 presents a CONSORT schematic for Study 1
(Fig. 1a) and Study 2 (Fig. 1b). Each study was per-
formed at the Exercise & Sport Nutrition Laboratory
(ESNL) at Texas A&M University after obtaining ethical
approval from the university’s ethics committee and
signed informed consent from each participant. Herein
we describe our overall procedures for each study
followed by a detailed methodology for each test used
within the studies (see below, Testing Methodology).
STUDY ONE: acute supplementation
Participants
Thirteen healthy and recreationally active men (age: 22
± 5 y, height: 177.8 ± 7.4 cm, weight: 84.1 ± 18.9 kg) were
recruited to participate in Study 1. Inclusion criteria re-
quired that each participant have at least 6 mo. of resist-
ance training immediately prior to entering the study
inclusive of performing bench press and leg press or
squats. Participants were excluded if they had a history
of treatment for metabolic disease, hypertension, thyroid
disease, arrhythmias, cardiovascular disease; currently
using any prescription medication, or had ingested creat-
ine within 6 wk of the intervention. Further exclusion
criteria also included women; a history of smoking; and
excessive alcohol consumption (>12 drinks/wk).
Familiarization session
Each participant initiated Study 1 by participating in a
familiarization session and was assessed for standard an-
thropological measurements including height, weight,
blood pressure, and heart rate. Participants also com-
pleted a general health screening form that was reviewed
by a registered nurse. Prior to baseline testing, each par-
ticipant completed a dietary record to include three
weekdays and one weekend day.
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Testing procedures
Participants were instructed to refrain from drinking al-
cohol, exercise, and non-steroidal anti-inflammatory
drugs (NSAIDs) for 48 h before testing. Testing was ini-
tiated by obtaining participant weight, body composition
measure (DXA), resting blood pressure (BP), and resting
heart rate (HR). Participants were then fitted with an in-
dwelling catheter for collection of a 20 mL blood sample
at time-0 prior to supplement ingestion.
Supplementation and assessment protocol
Upon completion of the pre-supplementation proce-
dures, each participant was randomized in a counterba-
lanced manner to ingest their respective supplements
providing 6.5 g total ingredients per dose. Treatments
consisted of a [1] placebo (PLA: 6.5 g dextrose), [2] cre-
atine monohydrate (CrM, 5 g creatine monohydrate,
1.5 g dextrose), [3] CrN-Low (1.5 g creatine nitrate, 5 g
dextrose) or [4] CrN-High (3 g creatine nitrate, 3.5 g
dextrose). All supplements were provided by Nutrabolt
(Bryan, TX). Following the ingestion of each respective
supplement, participants were placed into a semi-
recumbent position where HR and BP were measured
and blood was drawn in regular time increments of
30 min and then 1–5 h on the hour. All blood samples
were analyzed for standard blood chemistries to assess
hepatorenal and muscle enzyme function, as well as glu-
cose, and blood lipids. A complete blood count with
platelet differential was measured in addition to deter-
mining plasma nitrate and nitrite levels. All treatment
assessments were separated by at least a 7-d washout
period.
STUDY TWO: chronic supplementation
Participants
Forty-eight, healthy and recreationally active males
volunteered to participate in Study 2 (age: 21 ± 3 y,
height: 176.8 ± 5.8 cm, weight: 77.4 ± 20.9 kg). Base-
line testing followed a similar pattern to Study 1. Par-
ticipants also were asked to follow a standardized
resistance-training program 2 wk before their baseline
testing session (d-0) that was continued throughout
the supplementation period. Participants were further
requested not to change their dietary intake through-
out the investigation.
Familiarization testing
During the familiarization period, testing procedures
were initiated by explaining measurements for body
composition measurements, blood collection, biop-
sies, and exercise testing. Participants also completed
a 1-repetition maximum (1RM) bench press test and
a practice anaerobic sprint test on a cycle ergometer.
The strength test and anaerobic capacity procedures
are explained in greater detail below. Strength tests
were performed using a standardized isotonic lifting
protocol on an Olympic bench press [21]. Partici-
pants then were scheduled to return to the labora-
tory and were requested to start a standardized
resistance-training program 2 wk before their
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Fig. 1 CONSORT Schematic representation of Study 1 (a) and Study 2 (b)
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baseline laboratory visit. After the baseline testing
session (d-0) for Study 2 participants were assigned
randomly to one of the four treatment groups, pro-
viding 5.5 g total ingredients per dose. In Study 2,
participants were assigned randomly to [1] PLA (5 g
dextrose, 0.5 g flavoring), [2] CrM (3 g CrM, 0.5 g
flavoring, 2 g dextrose), [3] CrN-Low (1.5 g CrN,
0.5 g flavoring, 3.5 g dextrose), and [4] CrN-High
(3 g CrN, 0.5 g flavoring, 2 g dextrose). Exercise
testing occurred on baseline (d-0) and d-28.
Testing procedures
Participants arrived at the laboratory on the day before
baseline testing, at baseline (d-0), d-7, d-27, and d-28 for
a total of five laboratory visits. Percutaneous muscle
biopsies from the vastus lateralis occurred on the day
before baseline testing, d-7, and d-27 using a modified
Bergstrom needle biopsy technique following standard
procedures and subsequently examined for creatine con-
centrations [10]. Participants were requested to fast for
12 h and refrain from exercise, alcohol, and NSAIDs
consumption for 48 h prior to baseline, d-7, and d-28
testing. Participants turned in their food records upon
arrival to the lab at baseline, d-7, and d-28. Participants
were weighed and body composition was determined via
a DXA scan. Total body water was measured via bioelec-
trical impedance analysis (BIA). A fasted blood sample
was collected after determining body composition. On
d-7, participants completed the testing session with a
muscle biopsy. At baseline and d-28, after the blood
sample collection, participants continued with the exer-
cise tests, which consisted of a bench press test and an
anaerobic sprint test. Following their respective treat-
ment assignment, participants were requested to ingest
four doses of their respective supplements per day (at
approximately 0800, 1200, 1600, and 2000 h.) for the
first 7-d. Thereafter, participants ingested supplements
one time per day for the remainder of the study (d 8–28).
Nutrabolt (Bryan, TX) provided all of the supplements for
this study.
A side effect questionnaire was completed weekly for
the duration of the study. The questionnaires were
completed to determine how well participants tolerated
supplementation; how well participants followed the
supplementation protocol; and if participants experi-
enced any symptoms as a result of the supplement.
Supplement logs and verbal confirmation were used to
monitor compliance to the supplementation protocol.
After completing the first performance testing session at
baseline, participants were given their required supple-
ments and written directions on how to properly ingest
the supplements during the supplementation period.
Participants also engaged in a standardized, 4 d/wk, split
routine, encompassing upper and lower body workouts
for a total of 6 wk. Training logs were completed and
maintained by each participant to detail each training
session workload. A training partner or fitness instructor
monitored the training sessions to verify each session
was completed.
Testing methodology
Anaerobic capacity
After completion of the third bench press set, partici-
pants rested for ~5 min before starting the anaerobic
sprint test on a Lode Excalibur Sport 925900 cycle
ergometer (Lode BV, Groningen, The Netherlands). The
anaerobic sprint test consisted of a 3-min warm-up
comprised of pedaling at 60 – 70 rpm against a resist-
ance of 50 W for the first minute, 75 W for the second
minute, and 100 W for the third minute. The test con-
sisted of six sprints, lasting 6-sec each, interspersed with
a 30-sec rest between each repetition. Participants were
then allowed to rest for 3 min before initiating a Win-
gate test. Participants practiced the anaerobic sprint test
during the familiarization session. They were given de-
tailed instructions and verbal encouragement to pedal as
fast as possible, at an ‘all out’ pace at each sprint during
the anaerobic sprint test.
During the six, 6-sec sprints and the Wingate test (30-
sec sprint), each participant pedaled, all out, against a
standard workload of 7.5 J/kg/rev on the Lode ergom-
eter. To initiate the test, we instructed each individual to
pedal as fast as possible, at an ‘all out’ pace prior to ap-
plication of the workload and then sprint as fast as pos-
sible (all out) for the duration of each sprint. Test-to-test
variability in performing repeated Wingate anaerobic
capacity tests in our lab have yielded correlation coeffi-
cients of r = 0.98 ± 15 % for mean power. Following each
test, we recorded the seat height, pedal position, and
handlebar height to use for each testing session.
Anthropometry
Standardized anthropological testing included assess-
ments for body mass and height on a calibrated scale
(Cardinal Detecto Scale Model 8430, Webb City, MO)
and body composition via DXA (excluding cranium;
Hologic Inc., Waltham, MA). Test/retest reliability stud-
ies performed on male athletes with DXA yielded mean
deviation for total bone miner content and total fat-free/
soft tissue mass of 0.31-0.45 %, with a mean intra-class
correlation of 0.985 [1].
Blood collection procedures
Participants provided a (8 h) fasted blood sample via
venipuncture, using intravenous (IV) catheterization (BD
Insyte Autoguard, Bection, Dickinson and Company,
Franklin Lakes, NJ) from the antecubital vein in the
forearm according to standard phlebotomy procedures.
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Approximately 20 mL of whole blood was collected at
each time point (i.e., 0 [unsupplemented], 0.5, 1, 2, 3,
4, 5 h) in three, pre-chilled, 10-mL (18 mg K2
ethylene-diaminetera-acetic acid) tubes (BD Hemogard,
Franklin Lakes, New Jersey). The 10-mL EDTA tubes
were pre-chilled on ice and immediately placed back
on ice after each blood sampling period. Two collection
tubes were centrifuged at 3000 x g for 10 min at 4 °C
within 3 min of collection. Plasma was extracted and
stored at −80 °C for later analysis. The third collection
tube was stored at 4 °C for approximately 5 h and
analyzed for a complete blood count with platelet
differential.
Blood chemistry
All blood samples were analyzed for standard blood
chemistries inclusive of alkaline phosphatase (ALP),
aspartate transaminase (AST), alanine transaminase
(ALT), creatinine, blood urea nitrogen (BUN), creatine
kinase (CK), lactate dehydrogenase (LDH), glucose,
and blood lipids (total cholesterol, high density lipo-
protein [HDL], low density lipoprotein [LDL], triglyc-
erides [TG] using a Cobas® c 111 (Roche Diagnostics,
Basel, Switzerland).
The Cobas® automated clinical chemistry analyzer
was calibrated according to manufacturer guidelines.
This analyzer has been known to be valid and reliable
in previously published reports [15]. The internal
quality control for the Cobas c 111 was performed
using two levels of control fluids purchased from the
manufacturer to calibrate acceptable SD and coeffi-
cients of variation (CV) values for all aforementioned
assays. Samples were re-run if the observed values
were outside control values and/or clinical norms ac-
cording to standard procedures. Participants were also
given questionnaires at each time point of the study
to assess how well participants tolerated supplementa-
tion, how well participants followed the supplementa-
tion protocol, and if participants experienced any
symptoms as a result of the supplementation.
A complete blood count with platelet differential
(hemoglobin, hematocrit, red blood cell counts, MCV,
MCH, MCHC, RDW, white blood cell counts, lympho-
cytes, granulocytes, and mid-range absolute count
(MID) was measured using a Abbott Cell Dyn 1800
(Abbott Laboratories, Abbott Park, IL, USA) automated
hematology analyzer. The internal quality control for
Abbott Cell Dyn 1800 was performed using three levels
of control fluids purchased from manufacturer to cali-
brate acceptable SD and CV values for all whole blood
cell parameters. Calorimetric assay kits were used to
measure plasma creatine (Sigma-Aldrich, St. Louis, MO)
and plasma nitrate (Cayman Chemical, Ann Arbor, MI)
concentrations. These assays yielded mean CV value for
plasma nitrate (±3.21 %) and plasma creatine (±6.66 %)
with a test/retest correlation of r = 0.98 and r = 0.99 for
plasma nitrate and creatine, respectively.
Food frequency
A registered dietitian collected all food logs and analyzed
the results using dietary analysis software (ESHA Food
Processor Version 8.6, Salem, OR). Participants were
asked to record all food and beverage consumption for
three days and one weekend day prior to each testing
session during Study 1 and prior to baseline, d-7, and d-
28 during Study 2.
Muscle biopsies
During the study, we collected and analyzed muscle
biopsy samples to assay for creatine concentration.
All samples were collected while the participant was
in the supine position, where the region around the
biopsy site was shaved and sterilized with 3 povidone-
iodine swab sticks (Professional Disposables Inter-
national, Inc., Orangeburg, NY). Lidocaine HCl (1 %)
was injected underneath the skin, followed by an in-
jection through the fascia and to the epidermis using
a 10 mL syringe to anesthetize the biopsy region.
After approximately 5 – 10 min a small incision of
about 0.5 cm was made at the biopsy site using a
sterile scalpel (Aspen Surgical, Caldedonia, MI). Pres-
sure was applied with sterile gauze after the incision
was made. A 5 mm biopsy needle was inserted into
the incision and into the ‘belly’ of the vastus lateralis
muscle. Once the biopsy needle was pushed through
the fascia and settled into the correct location suction
was applied using 60 mL syringe, a small muscle
sample was collected with the biopsy needle. The
biopsy needle was in the muscle for approximately
5 – 20 sec until the procedure was completed.
After the biopsy was obtained, the sample was re-
moved from the needle by forcing air through the
syringe connected to the biopsy needle. The muscle
was quickly blotted on a sterile cover sponge to re-
move excess blood and then snap frozen into liquid
nitrogen. The sample was then stored at −80 °C for
later analysis. Immediately following the biopsy pro-
cedure, pressure was applied for at least 10 min to
the incision site to halt bleeding. After bleeding had
stopped, steristrips (3 M Health Care, St. Paul, MN)
were applied to ensure closure of the incision. A
tegaderm film (3 M Health Care, St. Paul, MN) was
placed over the steristrips, followed by gauze and a
self-adherent pressure bandage. Participants were pro-
vided with a biopsy care kit including multiple steri-
strips, tegaderm films, and the contact information of
the study coordinator.
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Muscle creatine analysis
Muscle samples were analyzed using mass spectropho-
tometer for muscle creatine (Cr). Samples were analyzed
based on methods developed by Harris and colleagues
[11, 12, 14]. The previously stored muscle samples were
placed in a vacuum centrifuge (Jouan RC1010 SpeedVac
Concentrator, Abbott Laboratories, Abbott Park, IL) and
centrifuged for approximately 4 h. Following the dehy-
dration process, the samples were powdered using a
mortar and pestle and then placed into pre-weight
microcentrifuge tubes. Perchloric acid (0.5 M) and a
1 mM ethylenediaminetetraacetic acid (EDTA) solution
were used to extract the muscle metabolites. The acid
solution was added to microcentrifuge tubes containing
the powered muscle. Microcentrifuge tubes were placed
on ice for 15 min with periodic vortexing. Samples were
centrifuged at 5,000 rpm for 5 min. The supernatant was
transferred into a pre-weighed microcentrifuge tube. A
2.1 M KHCO3 solution was used to neutralize the sam-
ples. The samples were then centrifuged a second time
at 5,000 rpm for 5 min. The supernatant was removed
and placed into a label microcentrifuge tube and stored
at −80 °C.
The samples were thawed at room temperature with
periodic vortexing. Extracts were assayed for Cr in pres-
ence of 50 mM imidazole buffer, pH 7.4; 5 mM magne-
sium chloride; 20 mM potassium chloride; 25 μM
phosphoenolpyruvate; 200 μM ATP; 45 μM NADH;
1250 U/mL lactate dehydrogenase; and 2,000 U/mL
pyruvate kinase. The reagents were individually added
into 1.5 mL cuvettes. The assay was then carried out
using 200 μL buffer, 100 μL potassium chloride, 25 μL
NADH, 20 μL ATP, 10 μL phosphoenolpyruvate, 2 μL
pyruvate kinase, 2 μL lactate dehydrogenase, 150 μL
water, and 100 μL of muscle extract. Changes in absorb-
ance were recorded with a Beckman Coulter DU 7400
Diode Array Spectrophotometer (Brea, California, USA)
at a wavelength of 339 nm. 20 μL of creatine kinase (25
U/mg) was added after the initial reading. The solution
was read every 5 min for 20 min for post-reaction ab-
sorbance values. Test-to-test assay variability yielded
mean CV values for muscle creatine (±3.69 %) with a
test/retest correlation of r = 0.946.
Side effects
The side effects questionnaire was completed after
each post-supplementation blood sampling period
during Study 1 (acute supplementation). In other
words, during Study 1, a side effects questionnaire
was completed at 0.5, 1, 2, 3, 4, and 5 h post-
supplementation. During Study 2 (chronic supplemen-
tation), a side effects questionnaire was completed
weekly, at d-7, d-14, d-21, and d-28 of supplementa-
tion. The questionnaire was completed to determine
how well participants tolerated supplementation; how
well participants followed the supplementation proto-
col; and if participants experienced any adverse symp-
toms during the supplementation period. Participants
were asked to rank the frequency and severity of their
symptoms – dizziness, headache, tachycardia, heart
skipping or palpitations, shortness of breath, nervous-
ness, blurred vision, and unusual or adverse effects.
Participants were requested to rank their symptoms
with 0 (none), 1 (minimal: 1-2/wk), 2 (slight: 3-4/wk),
3 (occasional: 5-6/wk), 4 (frequent: 7-8/wk), or 5
(severe: 9 or more/wk).
Strength testing and bench press test
Strength testing was performed on a bench press during
the familiarization session when participants completed
a 1-repetition maximum (1RM) using standardized iso-
tonic Olympic bench press procedure [21]. Participants
warmed-up by performing 10 repetitions at 50 % of their
estimated 1RM, 5 repetitions using 70 % of their
estimated 1RM, and 1 repetition using 90 % of their esti-
mated 1RM. One RM was determined within 5, one-
repetition sets following the warm-up. Our bench press
procedures show low day-to-day mean coefficients of
variation and high reliability in our lab (1.1 %, intra-
class, r = 0.99). Bench press testing was performed at
baseline and d-28. The bench press test, which only took
place at baseline and d-28, consisted of three total sets
using a 70 % 1RM load. Two sets of ten repetitions
followed by one set of repetitions to failure were per-
formed. Participants had a 2-min rest period between
sets. Peak power, average power, and average velocity
were measured during each repetition of the three sets
with a Tendo Fitrodyne.
Strength training procedures
All participants were required to follow the same resist-
ance training routine. The resistance training routine
consisted of exercise 4 d/wk split into two upper and
two lower body workouts per week for a total of 6 wk.
The 6 wk training protocol was periodized in 3 wk in-
crements consisting of selected exercises for the follow-
ing muscle groups. Upper body training consisted of two
chest exercises, two back exercises, one shoulder exer-
cise, one biceps exercise, one triceps exercise, and one
abdominal exercise. Lower body training consisted of
two-quadriceps exercises, two hamstring exercises, and
one calf exercise. Each exercise consisted of three sets of
10 repetitions (wk 1–3) or 8 repetitions (wk 4–6) per-
formed with as much weight as the participant could
perform per set. Individual training logs were main-
tained throughout the intervention and a training part-
ner or fitness instructor confirmed completion of each
training session.
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Supplementation protocol
Participants were assigned in a double-blind and counter-
balanced manner to ingest [1] PLA (5 g dextrose, 0.5 g fla-
voring), [2] CrM (3 g CrM, 0.5 g flavoring, 2 g dextrose),
[3] CrN-Low (1.5 g CrN, 0.5 g flavoring, 3.5 g dextrose),
and [4] CrN-High (3 g CrN, 0.5 g flavoring, 2 g dextrose).
Participants were asked to ingest 4 doses per day (at
approximately 0800, 1200, 1600, and 2000 h) during the
loading phase (d-0 [after baseline testing session]
through d-7). During the loading phase participants
ingested a total of [1] PLA (26 g dextrose/d), [2]
CrM (12 g CrM + 2 g flavoring + 8 g dextrose/d), [3]
CrN-Low (6 g CrN + 2 g flavoring + 14 g dextrose/d),
and [4] CrN-High (12 g CrN + 2 g flavoring + 8 g dex-
trose/d). Thereafter, participants ingested supplements
one dose daily at 0800 (maintenance phase) for the
remainder of the study (d-8 – d-28). During the
maintenance phase participants ingested a daily total
of [1] PLA (6.5 g dextrose), [2], CrM (3 g CrM +
0.5 g flavoring + 2 g dextrose), [3] CrN-Low (1.5 g
CrN + 0.5 g flavoring + 3.5 g dextrose), [4] CrN-High
(3 g CrN + 0.5 flavoring + 2 g dextrose). Participants
were instructed to take the supplements at the
assigned time and to take it as soon as possible if the
proper timing was missed. All supplements were
provided by Nutrabolt (Bryan, TX).
Total body water
Total body water was determined under standardized
conditions using an ImpediMed DF50 bioelectrical
impedance analyzer (BIA, ImpediMed, San Diego,
CA, USA). Participants were stationed in a supine
position with four electrodes placed on the wrists
and ankles. Bioelectrical impedance analysis has been
shown to be a valid method of determining total
body water [29].
Statistical analysis
Data analysis
Prior to initiation of the study, we ran a priori
power analysis, which indicated the appropriate sam-
ple size estimates for Study 1 and Study 2. All statis-
tical analysis was completed utilizing SPSS 22.0
(IBM Statistics, Chicago, IL). Study data were ana-
lyzed using a repeated measured multivariate analysis
of variance (MANOVA). Delta and percent change
values were calculated and used to determine
changes from baseline, which were analyzed by re-
peated measures analysis of variance (ANOVA). Par-
ticipant baseline demographic data were analyzed
using one-way ANOVA. Overall MANOVA effects
were examined as well as MANOVA univariate
group effects for certain variables when significant
interactions were seen. Greenhouse-Geisser univariate
tests of within-subjects time and group x time effects
and between-subjects univariate group effects were
reported for each variable analyzed within the MAN-
OVA model. Data were considered statistically signifi-
cant when the probability of type I error was 0.05 or
less and statistical trends were considered when the
probability of error ranged between p > 0.05 to p <
0.10. When a significant group, treatment and/or
interaction alpha level was observed, Tukey’s least sig-
nificant difference post-hoc analysis was performed to
determine where significance was obtained. Lastly, we
performed an analysis for relevant clinical chemistries
denoting lipids, glucose, muscle and hepatorenal en-
zyme function changes exceeding normal clinical
limits concordant to supplementation for changes
from (a) baseline to d-7, (b) baseline to d-28, and (c)
d-7 to d-28 using chi-square analyses. Data are pre-
sented as mean ± SD, mean change ± 95 % confidence
intervals as appropriate and frequency for chi-square
analyses.
Results
Study 1: acute supplementation
Twenty-two participants were initially recruited for
Study 1, and all completed consent forms, and partici-
pated in the required familiarization session. Of the ori-
ginal 22 participants, 13 completed Study 1 (Fig. 1).
Seven participants dropped out after the familiarization
session due to time constraints and one participant did
not pass medical screening due to Crohn’s disease. One
participant was excluded after being randomized into a
treatment group due to missing scheduled testing ses-
sions. None of the participants dropped out of the study
due to side effects related to the study protocol or
supplementation.
Plasma creatine and nitrate
Figure 2 shows the plasma creatine area under the curve
(AUC) after acute supplementation. The plasma creatine
AUC for CrM (5,634.4 ± 1,949.8 μmol/L) was significantly
greater than PLA (1,012.4 ± 1,882.2 μmol/L, p = 0.001),
CrN-Low (2,342.0 ± 3,133.3 μmol/L, p = 0.004), and
CrN-High (1,761.7 ± 3,408.8 μmol/L, p = 0.007). There
were no significant differences in plasma creatine
AUC among PLA, CrN-Low, and CrN-High. Figure 2
also shows the plasma nitrate AUC after acute sup-
plementation. The plasma nitrate AUC for CrN-High
(1,988.2 ± 1,618.8 μmol/L) was significantly greater
than CrM (48.0 ± 73.1 μmol/L, p = 0.001) and PLA
(51.4 ± 83.4 μmol/L, p = 0.001), but not significantly
different than CrN-Low (898.8 ± 1,688.9 μmol/L, p =
0.10). Although there was a trend towards a greater
AUC with CrN-Low there was no significant differ-
ence compared to PLA (p = 0.099) or CrM (p = 0.091).
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Hematologic profile
Findings for participant hepatorenal muscle enzymes, and
lipids are presented in Table 1. There were no significant
time effects for AST (p = 0.12), CK (p = 0.06), and
LDH (p = 0.40). However, there were significant time effects
for ALP (p < 0.001), ALT (p = 0.001), BUN (p < 0.001),
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Fig. 2 Data represent mean ± SD plasma creatine (a) and plasma nitrate (b) area-under-the-curve over 5 h post ingestion. Statistical notations
(p < 0.05 considered significant): (#) denotes a significant difference from PLA, CrN-Low, and CrN-High. (§) denotes a significant difference from
PLA and CrM
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Table 1 Hemodynamic and hematological response to supplementation for Study 1
Time (hours)
Group 0 0.5 1 2 3 4 5 Interaction p-Level
Hemodynamics
HR PLA 59.7 ± 8.2 60.1 ± 7.4 58.8 ± 7.7 57.2 ± 5.3 58.0 ± 7.4 54.8 ± 6.4 56.0 ± 7.3 Group 0.23
(b/min) CrM 63.8 ± 11.8 60.9 ± 5.7 59.9 ± 8.2 58.2 ± 7.0 56.3 ± 6.8 59.6 ± 8.8 58.5 ± 10.0 Time 0.15
CrN-Low 60.0 ± 8.4 57.9 ± 8.3 58.8 ± 9.0 56.3 ± 6.0 56.3 ± 6.0 56.9 ± 5.7 55.1 ± 5.9 Group × Time 0.59
CrN-High 59.1 ± 9.0 56.7 ± 7.4 57.9 ± 5.8 58.6 ± 3.8 58.0 ± 4.1 56.8 ± 4.7 57.5 ± 3.8
Systolic BP PLA 114.8 ± 6.2 113.9 ± 5.6 112.6 ± 4.9 116.5 ± 6.7 116.0 ± 4.8 117.2 ± 8.5 115.5 ± 5.2 Group 0.37
(mm Hg) CrM 114.6 ± 5.1 112.6 ± 4.4 112.2 ± 4.2 114.9 ± 5.3 112.9 ± 6.1 113.1 ± 5.8 114.9 ± 3.8 Time 0.02
CrN-Low 115.9 ± 6.1 113.1 ± 4.1 111.9 ± 5.2 113.5 ± 6.9 114.6 ± 6.9 114.62 ± 5.0 112.5 ± 3.5 Group × Time 0.39
CrN-High 115.4 ± 6.7 114.2 ± 5.5 111.4 ± 6.6 112.5 ± 6.0 113.5 ± 6.2 113.7 ± 9.7 114.2 ± 7.0
Diastolic BP PLA 73.1 ± 6.6 71.9 ± 7.5 72.2 ± 6.6 72.3 ± 7.3 73.1 ± 6.6 74.0 ± 5.5 72.3 ± 5.7 Group 0.66
(mm Hg) CrM 70.3 ± 6.6 71.5 ± 7.8 72.5 ± 4.1 73.9 ± 5.4 72.8 ± 6.0 73.9 ± 5.0 74.5 ± 4.0 Time 0.29
CrN-Low 72.2 ± 6.5 73.5 ± 5.4 71.9 ± 6.1 75.5 ± 5.4 74.3 ± 6.2 74.5 ± 4.6 73.1 ± 4.1 Group × Time 0.18
CrN-High 73.1 ± 7.9 77.1 ± 4.8 73.9 ± 6.5 74.5 ± 5.2 73.7 ± 6.1 72.2 ± 7.9 72.9 ± 4.8
Lipids
Total-C PLA 153.8 ± 28.4 156.2 ± 31.1 161.0 ± 31.8 162.5 ± 32.9 164.5 ± 31.2 164.6 ± 36.7 165.0 ± 36.1 Group 0.59
(mg/dl) CrM 156.8 ± 29.3 157.2 ± 29.3 160.7 ± 34.3 157.2 ± 31.4 159.3 ± 30.4 160.3 ± 32.8 160.2 ± 28.3 Time 0.06
CrN-Low 154.5 ± 27.6 154.2 ± 28.0 155.7 ± 31.7 156.0 ± 27.8 158.6 ± 28.9 158.5 ± 26.8 159.5 ± 27.9 Group × Time 0.77
CrN-High 158.3 ± 30.0 163.2 ± 27.0 162.3 ± 32.6 159.9 ± 26.9 163.9 ± 32.6 162.9 ± 26.8 163.5 ± 27.9
HDL-C PLA 55.8 ± 15.3 58.2 ± 15.6 58.8 ± 17.4 59.9 ± 16.1 61.0 ± 15.7 61.6 ± 17.0 62.2 ± 17.9 Group 0.29
(mg/dl) CrM 53.9 ± 17.1 54.1 ± 16.7 55.6 ± 18.4 55.1 ± 17.2 56.0 ± 17.1 56.9 ± 17.6 56.4 ± 18.8 Time 0.001
CrN-Low 51.0 ± 14.1 50.8 ± 15.6 51.2 ± 15.0 52.1 ± 14.9 53.8 ± 14.5 54.9 ± 15.2 55.3 ± 15.8 Group × Time 0.64
CrN-High 52.9 ± 17.5 54.7 ± 17.0 54.2 ± 16.8 54.2 ± 17.3 55.4 ± 16.9 55.2 ± 16.3 55.4 ± 17.7
Total-C/HDL-C PLA 2.9 ± 0.8 2.8 ± 0.8 2.9 ± 0.8 2.8 ± 0.8 2.8 ± 0.8 2.8 ± 0.8 2.8 ± 0.8 Group 0.40
Ratio CrM 3.1 ± 1.0 3.1 ± 0.9 3.1 ± 0.9 3.0 ± 0.8 3.0 ± 0.8 3.0 ± 0.8 3.1 ± 0.9 Time 0.09
(mg/dl) CrN-Low 3.3 ± 1.2 3.3 ± 1.1 3.3 ± 1.0 3.2 ± 1.0 3.2 ± 1.0 3.1 ± 1.0 3.1 ± 1.0 Group × Time 0.62
CrN-High 3.3 ± 1.4 3.3 ± 1.4 3.3 ± 1.4 3.3 ± 1.5 3.3 ± 1.4 3.3 ± 1.5 3.3 ± 1.5
LDL-C PLA 94.0 ± 26.3 96.5 ± 27.6 98.1 ± 28.1 100.1 ± 29.1 102.4 ± 32.6 102.5 ± 32.3 102.2 ± 32.0 Group 0.72
(mg/dl) CrM 99.1 ± 25.6 99.0 ± 24.1 102.5 ± 27.7 101.1 ± 24.7 102.0 ± 23.7 103.8 ± 26.5 102.5 ± 22.9 Time 0.06
CrN-Low 97.2 ± 23.0 97.1 ± 22.4 98.8 ± 24.0 100.0 ± 22.4 102.4 ± 23.1 102.6 ± 21.6 104.4 ± 22.5 Group × Time 0.67
CrN-High 102.7 ± 27.1 105.3 ± 25.8 105.0 ± 29.8 104.1 ± 26.6 101.5 ± 43.7 106.0 ± 27.0 105.4 ± 25.8
Triglyceride PLA 79.2 ± 26.2 82.1 ± 27.9 78.8 ± 24.8 73.9 ± 23.5 72.6 ± 21.0 71.8 ± 22.1 71.1 ± 22.6 Group 0.60
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Table 1 Hemodynamic and hematological response to supplementation for Study 1 (Continued)
(mg/dl) CrM 90.7 ± 33.1 88.1 ± 34.1 86.6 ± 30.9 76.2 ± 27.3 72.5 ± 25.9 73.7 ± 27.2 68.9 ± 22.6 Time 0.01
CrN-Low 88.3 ± 36.9 94.5 ± 37.9 90.6 ± 34.7 79.4 ± 25.3 75.4 ± 20.4 73.2 ± 18.3 72.8 ± 17.9 Group × Time 0.66
CrN-High 79.4 ± 25.6 86.1 ± 34.1 81.8 ± 29.1 73.0 ± 18.3 70.9 ± 19.5 71.9 ± 19.4 70.2 ± 20.3
Glucose PLA 95.8 ± 10.3 103.0 ± 10.4 92.1 ± 8.0 92.2 ± 5.5 91.5 ± 4.0 85.9 ± 26.1 91.9 ± 4.3 Group 0.33
(mg/dl) CrM 96.3 ± 9.9 85.3 ± 27.0 91.4 ± 6.0 89.8 ± 5.1 91.4 ± 5.4 91.6 ± 5.6 91.2 ± 4.9 Time 0.01
CrN-Low 96.3 ± 5.5 102.6 ± 8.1 94.1 ± 5.9 91.8 ± 6.5 91.2 ± 6.8 92.9 ± 6.7 92.1 ± 6.2 Group × Time 0.12
CrN-High 94.7 ± 7.5 96.1 ± 6.4 91.4 ± 6.2 91.1 ± 4.0 90.6 ± 5.4 91.3 ± 4.2 83.8 ± 25.3
Hepatorenal function
ALP PLA 7.9 ± 6.5 11.5 ± 8.0 11.9 ± 8.8 13.3 ± 9.1 13.9 ± 9.9 14.3 ± 9.4 16.9 ± 14.1 Group 0.23
(U/L) CrM 14.7 ± 9.1 15.9 ± 11.7 15.9 ± 10.4 16.8 ± 12.9 20.5 ± 14.4 25.4 ± 15.3 24.6 ± 14.9 Time 0.001
CrN-Low 12.3 ± 9.3 16.3 ± 10.3 20.3 ± 10.8 18.7 ± 11.5 21.7 ± 10.9 20.6 ± 10.2 22.8 ± 10.5 Group × Time 0.65
CrN-High 12.8 ± 8.1 17.5 ± 9.5 16.1 ± 8.2 17.2 ± 11.2 16.2 ± 9.7 17.2 ± 15.6 20.1 ± 18.1
ALT PLA 19 ± 8.2 19.5 ± 9.1 20.2 ± 9.6 19.6 ± 8.5 20.2 ± 9.7 20.3 ± 9.3 20.2 ± 9.3 Group 0.70
(U/L) CrM 20.3 ± 7.3 20.5 ± 7.7 21.4 ± 7.8 21.1 ± 8.4 21.1 ± 8.4 21.0 ± 7.9 21.2 ± 8.7 Time 0.001
CrN-Low 20.1 ± 7.7 20.63 ± 8.4 20.7 ± 8.5 20.8 ± 8.1 21.3 ± 8.2 21.0 ± 8.3 21.1 ± 8.0 Group × Time 0.66
CrN-High 21.2 ± 8.5 21.3 ± 8.3 21.5 ± 8.7 21.9 ± 8.6 21.1 ± 8.5 22.6 ± 8.8 22.7 ± 8.8
AST PLA 24.7 ± 4.9 23.8 ± 5.3 25.1 ± 4.7 25.4 ± 5.8 25.5 ± 5.8 25.2 ± 6.2 25.5 ± 6.1 Group 0.40
(U/L) CrM 25.9 ± 7.9 26.5 ± 8.8 27.1 ± 8.9 26.0 ± 9.1 26.3 ± 8.8 26.5 ± 8.6 27.0 ± 9.5 Time 0.12
CrN-Low 24.1 ± 6.1 24.6 ± 6.3 23.9 ± 5.9 24.7 ± 6.1 24.8 ± 5.3 24.3 ± 5.6 24.6 ± 5.4 Group × Time 0.64
CrN-High 28.0 ± 15.6 28.8 ± 16.3 28.7 ± 16.4 28.8 ± 14.8 29.6 ± 15.2 28.9 ± 14.8 29.8 ± 16.0
CK PLA 260 ± 222 264 ± 231 266 ± 219 262 ± 210 259 ± 211 254 ± 200 247 ± 193 Group 0.40
(U/L) CrM 160 ± 220 262 ± 222 263 ± 212 240 ± 207 249 ± 195 242 ± 189 237 ± 185 Time 0.06
CrN-Low 265 ± 275 270 ± 273 272 ± 287 267 ± 271 266 ± 273 256 ± 250 255 ± 252 Group × Time 0.51
CrN-High 490 ± 931 505 ± 958 497 ± 940 475 ± 864 470 ± 863 453 ± 809 470 ± 894
LDH PLA 168 ± 40 158 ± 24 170 ± 27 172 ± 26 169 ± 22 171 ± 30 171 ± 27 Group 0.08
(U/L) CrM 168 ± 21 164 ± 31 168 ± 31 162 ± 23 164 ± 28 165 ± 31 172 ± 29 Time 0.39
CrN-Low 146 ± 25 165 ± 31 155 ± 19 161 ± 23 160 ± 18 158 ± 22 159 ± 18 Group × Time 0.40
CrN-High 169 ± 36 179 ± 42 183 ± 40 167 ± 47 196 ± 74 176 ± 32 180 ± 27
BUN PLA 14.4 ± 4.8 14.0 ± 4.2 14.0 ± 4.3 13.4 ± 4.5 13.2 ± 4.2 12.8 ± 4.1 12.3 ± 3.8 Group 0.28
(mg/dl) CrM 15.2 ± 5.0 14.8 ± 4.6 14.6 ± 4.7 13.7 ± 4.5 13.4 ± 4.3 13.1 ± 4.3 12.6 ± 4.0 Time 0.001
CrN-Low 13.5 ± 4.8 13.0 ± 4.5 12.8 ± 4.5 12.2 ± 4.1 12.1 ± 4.1 11.6 ± 3.8 11.4 ± 3.8 Group × Time 0.76
CrN-High 14.6 ± 5.1 14.5 ± 5.22 14.1 ± 4.9 13.7 ± 5.1 13.2 ± 4.6 12.9 ± 4.3 12.7 ± 4.3
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Table 1 Hemodynamic and hematological response to supplementation for Study 1 (Continued)
Creatinine PLA 1.00 ± 0.15 0.99 ± 0.16 0.99 ± 0.15 0.98 ± 0.15 0.98 ± 0.15 0.98 ± 0.17 0.95 ± 0.14d Group 0.001
(mg/dl) CrM 0.99 ± 0.18 1.04 ± 0.17 1.04 ± 0.19 1.01 ± 0.19 0.99 ± 0.17 0.99 ± 0.17 1.00 ± 0.17 Time 0.001
CrN-Low 1.01 ± 0.19 1.08 ± 0.18 1.09 ± 0.17a,d 1.05 ± 0.16a 1.05 ± 0.17a 1.02 ± 0.18a 1.01 ± 1.16 Group × Time 0.001
CrN-High 1.05 ± 0.14a 1.11 ± 0.15a,b 1.17 ± 0.14a,b,c 1.12 ± 0.16a,b,c 1.06 ± 0.16a 1.03 ± 0.13a 1.02 ± 0.14
BUN: Creatinine PLA 14.4 ± 4.2 14.2 ± 4.1 14.3 ± 4.1 13.7 ± 3.9 13.5 ± 3.6 13.1 ± 3.4 12.9 ± 3.2 Group 0.11
(mg/dl) CrM 15.3 ± 4.3 14.5 ± 4.3 14.2 ± 3.9 13.7 ± 4.1 13.6 ± 4.2 13.4 ± 4.1 12.7 ± 3.5 Time 0.001
CrN-Low 13.7 ± 5.4 12.2 ± 4.6 11.9 ± 4.6 11.8 ± 4.3 11.8 ± 4.4 11.7 ± 4.1 11.5 ± 4.0 Group × Time 0.08
CrN-High 14.0 ± 4.8 13.2 ± 4.6 12.0 ± 3.9 12.3 ± 4.0 12.6 ± 3.9 12.5 ± 3.8 12.5 ± 3.9
Data are mean ± SD. To convert respective values to mmol/L multiply total cholesterol, HDL-C and LDL-C to mmol/L multiply by 0.0259; triglycerides by 0.0113, BUN by 0.357 and glucose by 0.0555. To convert ALP,
ALT, AST, CK, LDH, to μkat/L multiply by 0.0167. To convert creatinine to μmol/L multiply by 88.54. p < 0.05 is considered significant
Statistical notations. adenotes a significant difference from PLA. bdenotes a significant difference from CrM. cdenotes a significant difference from CrN-Low. ddenotes a significant difference from CrM, CrN-Low,
and CrN-High
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Table 2 Anthropometry and blood lipid, glucose, nitrate, and creatine characteristics of Study 2 participants
Day
Variable Group Baseline 7 28 p-level
Body Weight PLA 77.3 ± 11.9 77.6 ± 12.1 77.4 ± 12.7 Group 0.003
(kg) CrM 81.7 ± 13.2 82.4 ± 13.4 82.6 ± 14.0 Time 0.002
CrN-Low 72.0 ± 9.7 72.2 ± 9.9 72.7 ± 10.0 Group × Time 0.29
CrN-High 90.8 ± 13.4 90.8 ± 13.2 92.0 ± 14.3
Fat Mass PLA 12.7 ± 6.3 12.6 ± 6.3 12.7 ± 6.3 Group 0.02
(kg) CrM 12.9 ± 5.3 13.0 ± 5.5 13.2 ± 5.2 Time 0.17
CrN-Low 8.9 ± 4.7 8.7 ± 4.6 9.1 ± 4.7 Group × Time 0.90
CrN-High 16.5 ± 6.9 16.2 ± 6.4 16.6 ± 7.4
Fat-Free Mass PLA 58.1 ± 8.0 58.5 ± 8.0 58.3 ± 8.3 Group 0.01
(kg) CrM 62.4 ± 8.7 62.5 ± 8.8 62.9 ± 9.2 Time 0.02
CrN-Low 56.9 ± 7.4 57.4 ± 7.3 57.3 ± 7.3 Group × Time 0.50
CrN-High 67.4 ± 8.1 67.7 ± 8.2 68.5 ± 8.2
Body Fat PLA 17.8 ± 6.9 17.1 ± 6.7 17.2 ± 6.7 Group 0.07
(%) CrM 16.7 ± 4.0 16.8 ± 4.3 16.8 ± 3.7 Time 0.24
CrN-Low 13.1 ± 5.4 12.8 ± 5.2 13.2 ± 5.2 Group × Time 0.78
CrN-High 19.2 ± 5.9 18.7 ± 5.5 18.8 ± 6.3
Total Body Water PLA 51.3 ± 4.5 50.6 ± 5.1 52.5 ± 6.9 Group 0.18
(%) CrM 51.4 ± 3.3 50.8 ± 3.7 49.4 ± 8.4 Time 0.64
CrN-Low 52.9 ± 4.6 54.1 ± 5.1 52.7 ± 4.2 Group × Time 0.47
CrN-High 50.6 ± 6.5 48.8 ± 4.1 49.0 ± 4.7
Lipids, Glucose, Nitrate, and Creatine
Total-C PLA 165.0 ± 33.4 161.5 ± 38.8 164.6 ± 38.8 Group 0.19
(mg/dl) CrM 174.4 ± 25.5 175.4 ± 27.8 183.4 ± 41.1 Time 0.38
CrN-Low 151.9 ± 35.8 149.7 ± 29.5 150.0 ± 37.5 Group × Time 0.83
CrN-High 162.7 ± 25.1 155.9 ± 23.8 160.7 ± 29.1
HDL-C PLA 49.2 ± 11.4 50.6 ± 10.2 50.3 ± 12.8 Group 0.62
(mg/dl) CrM 51.8 ± 15.2 54.7 ± 15.5 55.2 ± 17.4 Time 0.36
CrN-Low 48.6 ± 15.7 48.3 ± 15.1 47.9 ± 12.8 Group × Time 0.85
CrN-High 46.7 ± 10.7 47.2 ± 12.3 48.7 ± 10.6
Total-C/HDL-C PL 3.45 ± 0.71 3.23 ± 0.64 3.30 ± 0.59 Group 0.82
Ratio CrM 3.70 ± 1.46 3.50 ± 1.34 3.69 ± 1.58 Time 0.24
(mg/dl) CrN-Low 3.26 ± 0.81 3.32 ± 1.04 3.29 ± 1.05 Group × Time 0.74
CrN-High 3.62 ± 0.82 3.47 ± 0.88 3.44 ± 0.94
LDL-C PLA 93.4 ± 23.4 91.7 ± 29.6 95.8 ± 34.6 Group 0.34
(mg/dl) CrM 103.8 ± 33.3 106.6 ± 33.5 112.2 ± 49.0 Time 0.36
CrN-Low 86.3 ± 22.6 84.8 ± 23.7 87.3 ± 28.7 Group × Time 0.88
CrN-High 95.2 ± 25.0 93.4 ± 22.9 94.3 ± 28.4
Triglyceride PLA 109.1 ± 52.5 98.2 ± 36.9 94.2 ± 19.1 Group 0.63
(mg/dl) CrM 114.5 ± 60.6 93.1 ± 30.9 112.0 ± 42.6 Time 0.16
CrN-Low 87.5 ± 43.2 90.7 ± 49.1 85.8 ± 30.7 Group × Time 0.69
CrN-High 104.8 ± 47.1 85.6 ± 39.2 97.2 ± 49.8
Glucose PLA 102.0 ± 18.6 102.1 ± 15.3 94.9 ± 12.6 Group 0.74
(mg/dl) CrM 97.5 ± 13.9 99.7 ± 15.1 100.4 ± 16.8 Time 0.70
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BUN: Creatinine ratio (p < 0.001), and glucose (p = 0.009).
No significant group x time interactions were observed
for ALP (p = 0.65), ALT (p = 0.66), AST (p = 0.64), CK
(p = 0.51), LDH (p = 0.40), BUN (p = 0.76), BUN:
Creatinine ratio (p = 0.08), and glucose (p = 0.12).
Significant time (p = 0.001) and group × time effects
(p = 0.001) were only observed for creatinine. Specif-
ically, CrN-High had significantly greater creatinine
concentration than PLA at time 0. The PLA group
had significantly lower creatinine concentration than
CrN-Low and CrN-High at 0.5 h. CrN-High had sig-
nificantly greater creatinine concentration than CrM
at 0.5 h. CrN-Low had significantly greater creatin-
ine concentration than PLA and CrM, but signifi-
cantly lower concentrations than CrN-High at 1 h.
Concentrations of creatinine in CrN-High were sig-
nificantly greater than PLA, CrM, and CrN-Low at
1 h and at 2 h. CrN-Low had significantly lower cre-
atinine concentration than PLA at 2, 3, 4, and 5 h.
Creatinine concentrations in CrN-High were signifi-
cantly greater than PLA at 4 and 5 h. No significant
time effects were observed for TC (p = 0.06), or the
ratio (p = 0.09), and LDL (p = 0.06). While we did ob-
serve a significant time effect for HDL-C (p = 0.001)
and TG (p = 0.007), no significant group × time in-
teractions were noted for any lipid variable.
Hemodynamic profile
Findings for heart rate (HR), systolic blood pressure
(SBP), and diastolic blood pressure (DBP) data are pre-
sented in Table 1. Overall, we observed a significant
trend for time as systolic blood pressure changed
throughout the study so that time 0 was greater than
0.5 h and 1 h post supplementation (p < 0.05). Further,
the 1 h assessment was significantly lower than SBP at 0,
2, 3, 4, and 5 h post-supplementation (all, p < 0.01). We
did not observe any significant trends for DBP and no
between group effects were noted for SBP or DBP at any
time point.
Study 2: chronic supplementation
Seventy-one participants were initially recruited for
Study 2 and completed consent forms, and all partic-
ipated in the required familiarization session. Of the
original 71 participants, 48 completed the study.
Twenty-three participants dropped out after the
familiarization, 22 due to time constraints and one
due to apprehension of the muscle biopsy procedure.
Fifty-three participants were randomized to the four
treatment groups. Twelve participants were initially
randomized to the PLA group, but one participant
was dropped due to missed scheduled laboratory
visits. Fifteen were initially randomized to the CrM
group. Four participants dropped out of this group,
one due to missed scheduled laboratory visits, one
developed abdominal pains after the second day of
supplementation, one due to a family emergency,
and one withdrew due to time constraints. There
were no withdraws from either creatine nitrate
(CrN) group.
Compliance, side effects, training, and diet
All participants were 100 % compliant with the ingestion
of the supplements and 99.4 % were compliant with the
proper timing of the supplements.
Our analysis of side effects examining the frequency
and severity of dizziness, headache, tachycardia, heart
skipping or palpitations, shortness of breath, nervous-
ness, blurred vision, and any other unusual or adverse
effects demonstrated no time (p = 0.35) or group × time
(p = 0.34) effects for any variable. However, some partici-
pants reported minimal (no greater than 1 in severity)
Table 2 Anthropometry and blood lipid, glucose, nitrate, and creatine characteristics of Study 2 participants (Continued)
CrN-Low 96.1 ± 8.5 96.1 ± 7.9 96.4 ± 17.9 Group × Time 0.27
CrN-High 97.1 ± 9.4 93.2 ± 5.2 96.0 ± 9.4
Nitrate PLA 4.5 ± 2.0 5.1 ± 3.3 9.0 ± 15.3 Group 0.001
(μmol/L) CrM 4.9 ± 3.6 3.8 ± 1.8 4.5 ± 1.8 Time 0.001
CrN-Low 5.6 ± 3.1 64.8 ± 30.9a,b 13.9 ± 13.9 Group × Time 0.001
CrN-High 4.3 ± 1.6 72.0 ± 47.3a,b 21.5 ± 28.9b
Creatine PLA 131.1 ± 92.2 143.5 ± 131.9 150.6 ± 152.0 Group 0.04
(μmol/L) CrM 165.2 ± 94.4c 504.9 ± 422.8d 231.2 ± 126.1 Time 0.001
CrN-Low 73.0 ± 56.4 170.4 ± 153.7 147.9 ± 95.3 Group × Time 0.01
CrN-High 120.3 ± 99.8 241.3 ± 131.9 251.9 ± 406.4
Data are mean ± SD. To convert respective values to mmol/L multiply total cholesterol, HDL-C and LDL-C multiply by 0.0259; triglycerides by 0.0113, BUN by 0.357
and glucose by 0.0555. To convert creatinine to μmol/L multiply by 88.54. p < 0.05 considered significant
Statistical notations. adenotes a significant difference from PLA. bdenotes a significant difference from CrM. cdenotes a significant difference from CrN-Low. dde-
notes a significant difference from PLA, CrN-Low, and CrN-High
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side effects such as dizziness, headache, tachycardia,
heart skipping or palpitations, shortness of breath, ner-
vousness, and blurred vision; however, these symptoms
where similar amongst the treatment groups over
the 28-d period (PLA = 11, CrM = 11, CrN-Low = 13,
CrN-High = 13).
Baseline Day 7  Day 28
-200
-100
0
100
200
300
400
500
600
700
800
900
1000
µm
ol
/L
PLA
CrM
CrN-Low
CrN-High
†
¥
-20
0
20
40
60
80
100
120
140
µm
ol
/L
PLA
CrM
CrN-Low
CrN-High
§
ø
A
B
Fig. 3 Data represent mean ± SD plasma creatine (a) and plasma nitrate (b) concentrations following 7 and 28 days supplementation. Statistical
notations (p < 0.05 considered significant): (¥) denotes CrM significantly greater than CrN-Low. (†) denotes CrM significantly greater than PLA,
CrN-Low, and CrN-High. (§) denotes CrN-Low and CrN-High significantly greater than PLA and CrM. (Ø) denotes CrN-High significantly greater
than CrM
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Table 3 Hepatorenal and blood cell characteristics of Study 2 participants
Day
Marker Group 0 7 28 p-level
Hepatorenal
ALPS PLA 11.2 ± 14.6 10.5 ± 10.7 12.4 ± 10.9 Group 0.44
(U/L) CrM 11.4 ± 9.5 12.0 ± 10.4 11.0 ± 7.8 Time 0.36
CrN-Low 15.5 ± 11.4 16.2 ± 11.9 19.5 ± 15.9 Group × Time 0.85
CrN-High 12.0 ± 7.1 13.6 ± 6.1 14.3 ± 11.7
ALT PLA 27.2 ± 8.6 30.2 ± 13.8 32.1 ± 30.6 Group 0.24
(U/L) CrM 28.9 ± 16.6 25.1 ± 10.0 32.7 ± 22.9 Time 0.06
CrN-Low 21.3 ± 6.7 19.9 ± 4.4 22.4 ± 6.7 Group × Time 0.70
CrN-High 28.7 ± 13.2 30.0 ± 15.7 36.8 ± 23.2
AST PLA 31.2 ± 13.3 30.1 ± 11.6 29.5 ± 13.4 Group 0.90
(U/L) CrM 28.3 ± 10.2 26.4 ± 7.7 32.5 ± 12.3 Time 0.56
CrN-Low 26.0 ± 7.0 30.6 ± 25.3 26.0 ± 6.0 Group × Time 0.47
CrN-High 26.4 ± 5.9 28.7 ± 7.0 32.0 ± 7.6
CK PLA 252 ± 128 294 ± 399 206 ± 161 Group 0.79
(U/L) CrM 285 ± 169 345 ± 319 409 ± 373 Time 0.35
CrN-Low 283 ± 169 480 ± 987 243 ± 136 Group × Time 0.56
CrN-High 284 ± 171 349 ± 203 424 ± 287
LDH PLA 226 ± 180 167 ± 29 158 ± 34 Group 0.93
(U/L) CrM 185 ± 62 172 ± 39 184 ± 48 Time 0.20
CrN-Low 175 ± 50 173 ± 41 166 ± 29 Group × Time 0.23
CrN-High 173 ± 29 176 ± 30 182 ± 39
BUN PLA 16.3 ± 3.6 15.6 ± 5.2 15.7 ± 4.9 Group 0.64
(mg/dl) CrM 15.3 ± 5.5 15.2 ± 4.9 16.3 ± 6.1 Time 0.48
CrN-Low 14.9 ± 3.8 13.3 ± 3.9 13.5 ± 4.6 Group × Time 0.64
CrN-High 14.6 ± 3.2 14.8 ± 2.7 15.7 ± 5.8
Creatinine PLA 1.18 ± 0.26 1.19 ± 0.33 1.15 ± 0.27 Group 0.97
(mg/dl) CrM 1.15 ± 0.46 1.26 ± 0.36 1.23 ± 0.39 Time 0.001
CrN-Low 1.09 ± 0.25 1.21 ± 0.31 1.23 ± 0.31 Group × Time 0.12
CrN-High 1.12 ± 0.18 1.15 ± 0.23 1.20 ± 0.23
BUN: Creatinine PLA 14.2 ± 3.7 13.9 ± 6.8 13.6 ± 3.1 Group 0.78
(mg/dl) CrM 13.7 ± 3.6 12.8 ± 5.3 14.0 ± 6.1 Time 0.07
CrN-Low 14.1 ± 4.2 11.4 ± 3.8 11.3 ± 3.4 Group × Time 0.13
CrN-High 13.3 ± 3.8 13.3 ± 3.3 13.4 ± 4.8
Blood cell characteristics
MCV PLA 92.2 ± 3.1 91.7 ± 3.7 91.6 ± 3.8 Group 0.79
(fL) CrM 93.0 ± 3.9 93.7 ± 3.9 93.6 ± 4.7 Time 0.47
CrN-Low 91.7 ± 3.8 91.8 ± 4.0 92.3 ± 4.2 Group × Time 0.49
CrN-High 93.3 ± 3.0 93.4 ± 3.1 88.7 ± 17.7
MCH PLA 30.4 ± 1.7 30.5 ± 1.3 31.0 ± 2.3 Group 0.45
(pg/cell) CrM 30.6 ± 1.4 31.2 ± 1.5 31.0 ± 2.6 Time 0.23
CrN-Low 30.6 ± 1.7 31.6 ± 2.1 31.3 ± 2.2 Group × Time 0.92
CrN-High 31.2 ± 0.9 31.3 ± 1.4 31.5 ± 1.2
Galvan et al. Journal of the International Society of Sports Nutrition  (2016) 13:12 Page 15 of 24
Dietary characteristics
We observed no significant time effects for daily
caloric (absolute: p = 0.38; relative: p = 0.37), protein
(absolute: p = 0.74; relative: p = 0.77), carbohydrate
(absolute: p = 0.23; relative: p = 0.15), and fat (absolute:
p = 0.41; relative: p = 0.57) intake. There were also no
significant group × time effects for daily caloric (absolute:
p = 0.89; relative: p = 0.94), protein (absolute: p = 0.40;
relative: p = 0.39), carbohydrate (absolute: p = 0.31; rela-
tive: p = 0.33), and fat (absolute: p = 0.64; relative: p = 0.54)
intake.
Clinical chemistry panels, plasma creatine plasma nitrates,
muscle creatine
Results for the plasma lipid, glucose, nitrate and cre-
atine are presented in Table 2 and Fig. 3 while corre-
sponding hepatorenal and blood cell characteristics
are presented in Table 3. As a whole, there were no
significant time or group × time effects for any blood
safety marker. There were significant group, time, and
group x time interactions for plasma nitrate and
plasma and intramuscular creatine concentrations (all,
P < 0.04). After 7-d of supplementation, there was a
significant increase in plasma nitrates in CrN-Low
(59.5 μmol/L, 95 % CI 42.6, 76.4) and CrN-High
(76.5 μmol/L, 95 % CI 50.7, 84.3) groups, with no con-
comitant increase observed for the PLA (0.49 μmol/L,
95 % CI −17.7, 18.6) and CrM groups (−1.1 μmol/L, 95 %
CI −19.2, 17.1, p < 0.001). By d-28, nitrate levels had
dropped for the CrN-Low group to a non-significant level
relative to baseline (8.52 μmol/L, 95 % CI, −1.9, 18.9),
while the CrN-High group remained elevated relative to
baseline, but at a concentration ~25 % of the d-7 value
(17.09 μmol/L, 95 % CI, 6.7, 27.4). Between group analysis
further demonstrated that while the CrN-High condition
remained significant relative to the CrM treatment (P <
Table 3 Hepatorenal and blood cell characteristics of Study 2 participants (Continued)
MCHC PLA 32.9 ± 1.2 33.3 ± 1.7 33.8 ± 1.8 Group 0.40
(g/dl) CrM 32.9 ± 0.7 33.3 ± 1.5 33.1 ± 1.9 Time 0.53
CrN-Low 33.3 ± 0.8 34.5 ± 3.4 33.9 ± 1.7 Group × Time 0.66
CrN-High 33.5 ± 0.7 33.5 ± 1.6 32.2 ± 6.0
RBCDW PLA 13.2 ± 0.5 13.1 ± 0.9 13.1 ± 0.3 Group 0.02
(%) CrM 13.5 ± 0.9 13.7 ± 0.9 13.9 ± 0.8 Time 0.11
CrN-Low 13.6 ± 0.6 13.4 ± 0.6 13.5 ± 0.7 Group × Time 0.66
CrN-High 12.8 ± 0.6 13.2 ± 0.6 13.1 ± 0.4
Platelet Count PLA 206 ± 36 188 ± 32 208 ± 70 Group 0.35
(x103/μL) CrM 234 ± 57 226 ± 91 255 ± 51 Time 0.56
CrN-Low 218 ± 69 183 ± 50 194 ± 68 Group × Time 0.39
CrN-High 220 ± 61 412 ± 713 224 ± 59
WBC PLA 6.2 ± 1.7 5.3 ± 1.5 6.2 ± 1.1 Group 0.72
(x103/μL) CrM 6.0 ± 1.7 6.6 ± 1.3 6.4 ± 1.3 Time 0.58
CrN-Low 6.2 ± 1.6 5.9 ± 1.8 5.4 ± 1.3 Group × Time 0.18
CrN-High 5.9 ± 1.4 5.5 ± 1.6 6.1 ± 1.6
RBC PLA 5.2 ± 0.8 5.01 ± 0.83 4.8 ± 0.6 Group 0.25
(x106/μL) CrM 5.3 ± 0.6 5.60 ± 0.97 5.1 ± 0.8 Time 0.09
CrN-Low 5.0 ± 0.5 5.11 ± 0.95 4.9 ± 0.7 Group × Time 0.65
CrN-High 5.5 ± 0.8 5.08 ± 0.51 5.1 ± 0.5
Hematocrit PLA 47.7 ± 7.1 46.0 ± 8.2 44.0 ± 4.5 Group 0.16
(%) CrM 49.5 ± 6.7 52.5 ± 9.7 47.6 ± 8.4 Time 0.51
CrN-Low 46.2 ± 5.5 47.1 ± 10.3 44.8 ± 7.1 Group × Time 0.44
CrN-High 51.2 ± 7.8 47.5 ± 5.2 51.7 ± 15.4
Hemoglobin PLA 15.7 ± 2.5 15.3 ± 2.7 14.8 ± 1.2 Group 0.17
(g/dl) CrM 16.3 ± 2.1 20.1 ± 10.2 15.7 ± 2.8 Time 0.63
CrN-Low 15.4 ± 2.1 16.1 ± 3.1 15.2 ± 2.3 Group × Time 0.19
CrN-High 17.2 ± 2.7 15.9 ± 1.4 18.7 ± 9.5
Data are mean ± SD
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Table 4 Assessment of blood chemistry changes denoting lipids, glucose, muscle and hepatorenal function concordant to
supplementation
Treatment
PLA CrM CrN-Low CrN-High Chi-Square
Cholesterol No Change 0 0 0 0 0.33
Normal Base; Exceed Day 7 10 8 12 13
Normal Base; Exceed Day 28 1 1 0 0
Normal Day7; Exceed Day 28 0 2 1 0
HDL-C No Change 6 9 10 10 0.72
Normal Base; Exceed Day 7 2 1 0 0
Lipids & glucose Normal Base; Exceed Day 28 1 0 1 1
Normal Day7; Exceed Day 28 2 1 2 2
LDL-C No Change 9 10 13 12 0.30
Normal Base; Exceed Day 7 0 0 0 0
Normal Base; Exceed Day 28 2 1 0 0
Normal Day7; Exceed Day 28 0 0 0 1
Triglycerides No Change 11 11 13 13 0.31
Normal Base; Exceed Day7 0 0 0 0
Normal Base; Exceed Day28 0 0 0 0
Normal Day7; Exceed Day28 0 0 0 0
Glucose No Change 10 9 11 11 0.56
Normal Base; Exceed Day 7 1 1 1 0
Normal Base; Exceed Day 28 0 1 0 0
Normal Day7; Exceed Day 28 0 0 1 2
LDH No Change 9 9 12 11 0.26
Normal Base; Exceed Day 7 1 0 0 0
Normal Base; Exceed Day 28 0 0 0 2
Normal Day7; Exceed Day 28 1 2 1 0
Creatine No Change 7 7 10 11 0.75
Kinase Normal Base; Exceed Day 7 2 1 1 0
Normal Base; Exceed Day 28 0 0 0 0
Normal Day7, Exceed Day 28 2 3 2 2
Muscle Creatinine No Change 11 9 11 11 0.32
Normal Base; Exceed Day 7 0 0 0 0
Normal Base; Exceed Day 28 0 1 0 2
Normal Day7; Exceed Day 28 0 1 2 0
Kidney BUN No Change 10 8 11 12 0.37
Normal Base; Exceed Day 7 0 0 1 0
Normal Base; Exceed Day 28 0 2 0 0
Normal Day7; Exceed Day 28 1 1 1 1
ALP No Change 11 11 13 13 0.32
Normal Base; Exceed Day 7 0 0 0 0
Normal Base; Exceed Day 28 0 0 0 0
Normal Day7; Exceed Day 28 0 0 0 0
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0.03), it no longer remained significant relative to the PLA
treatment (Table 2). Table 4 presents the assessment of
the blood chemistry changes in serum lipids, glucose,
muscle and hepatorenal function associated with supple-
mentation. No significant differences were noted between
groups for any analyte.
There was a significant increase in plasma creatine for
the CrM (312.0 μmol/L, 95 % CI 192.1, 432.0), CrN-Low
(126.5 μmol/L, 95 % CI, 15.1, 238.0), and CrN-High
groups at d-7 (120.9 μmol/L, 95 % CI 14.1, 227.8), all
three of which were significant relative to the PLA group
(7.7 μmol/L, 95 % CI, −110.0, 131.7, p < 0.03). By d-28,
only the CrN-High plasma creatine remained signifi-
cantly elevated relative to baseline (131.5 μmol/L,
95 % CI, 22.5, 240.5) while the CrM (39.0 μmol/L,
95 % CI, −83.4, 161.0) and CrN-Low (103.2 μmol/L,
95 % CI −10.5, 216.9) groups no longer demonstrated
a significant elevation. No between group differences
at d-28 were otherwise noted.
Intramuscular creatine was significantly increased
in the CrM (7.1 mmol/kg DW, 95 % CI, 3.1, 11.0)
and CrN-High (4.6 mmol/kg DW, 95 % CI, 0.8, 8.4)
groups and significantly decreased in the CrN-Low
group (−4.0 mmol/kg DW, 95 % CI −7.7, −0.3) while
no significant change was noted for the PLA group
(−2.5 mmol/kg DW, 95 % CI, −6.7, 1.7). Between
group post-hoc comparisons showed that the CrM
and CrN-High groups had significantly greater
concentrations relative to the PLA (p = 0.002) and
CrN-Low groups (p = 0.001). On d 28, the CrM
group remained the only group to have significantly
elevated muscle creatine (8.8 mmol/kg DW, 95 % CI,
5.5, 12.2), while the CrN-High group initial 7-d con-
centrations abated to a lower concentration (1.4,
95 % CI, −1.8, 4.7 mmol/kg DW). Both the CrN-Low
and PLA groups remained relatively unchanged.
Anthropometry
While body mass increased over time in all groups by d-
28, only the CrM and CrN-High groups had a significant
increase in FFM and lean mass, with the CrN-High
group significantly greater than the CrN-Low group for
both variables (Fig. 5).
Bench press performance, anaerobic sprint and Wingate test
Results for all exercise performance variables are pre-
sented in Table 5. Overall, we observed significant
time effects and group × time effects for several
strength testing variables. Specifically, we observed
significant increases in bench press lifting volume
(kg) to fatigue for all groups over the 28-d testing
period. Only the CrN-High group demonstrated sig-
nificance differences relative to the PLA group (Fig. 4).
Similar findings were noted for peak and average
bench press power output as determined by the
Tendo™ assessment. Interestingly, post-hoc analyses
demonstrated that the CrN-High changes were signifi-
cantly greater than PLA and CrN-Low (Fig. 4). No
significant treatment effects were observed for the
Wingate or anaerobic sprint tests.
Discussion and conclusions
The primary aim of our studies was to examine the
dose-dependent effects of CrN on acute and chronic in-
dices of safety and exercise performance. Accordingly,
we performed an acute safety study to assess basic
hematologic variables attesting to hepatorenal and
muscle enzyme function, blood glucose, lipids, and
hemodynamic variables, followed by 28-d of chronic
supplementation to examine safety and exercise per-
formance. In Study 1, there were no significant changes
in any blood marker or hemodynamic function for any
treatment group throughout 5 h of post-ingestion
follow-up (Table 1). Study 2 also included a 7-d loading
schema. Similar safety findings were observed in Study
2, with two exceptions: ALP and creatine kinase (see
below). While some side effects were reported, they were
distributed amongst all groups, including the PLA
group, and were reported to be minimal in regard to se-
verity. There also was a significant increase in several
Table 4 Assessment of blood chemistry changes denoting lipids, glucose, muscle and hepatorenal function concordant to
supplementation (Continued)
Liver ALT No Change 11 9 12 11 0.49
Normal Base; Exceed Day 7 0 0 0 0
Normal Base; Exceed Day 28 0 2 1 2
Normal Day7; Exceed Day 28 0 0 0 0
AST No Change 8 8 12 8 0.54
Normal Base; Exceed Day 7 1 0 1 0
Normal Base; Exceed Day 28 1 1 0 2
Normal Day7; Exceed Day 28 1 2 0 3
Data are presented as frequency. Statistical significance is detailed from chi-square analyses
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strength parameters for the CrM and CrN-High groups
in Study 2. Though the changes associated with CrM
and CrN-High were similar, the CrN-High group
reached significance when compared to the PLA group
for total lifting volume and Tendo™ average power out-
put (Fig. 4). A similar pattern for improvement was also
observed for FFM and lean mass (Fig. 5). The differences
observed, however, could not be attributed to greater
muscle creatine content in the CrN groups compared to
CrM. Based on these findings we accept both our
hypotheses that CrN is safe when provided up to 3 g/d
and is efficacious with regard to changes in strength and
body composition.
Several investigations have reported the effects of ni-
trate supplementation on blood pressure and heart rate
[23, 25, 31]. Though we observed a slight trend for a de-
crease in systolic blood pressure (SBP) (~3 mmHg) in all
treatment groups with no significant difference observed
among groups. No similar trend was noted for diastolic
blood pressure (DBP) or heart rate (HR), nor did we
Table 5 Bench press and anaerobic sprint performance characteristics of Study 2 participants
Group Day 0 Day 28 Interactions p-level
Bench press performance
Max reps PLA 10.8 ± 2.9 13.0 ± 4.8 Group 0.83
(@70 % 1RM) CrM 12.0 ± 5.5 15.0 ± 7.1 Time 0.001
CrN-Low 11.9 ± 2.7 14.0 ± 3.7 Group × Time 0.55
CrN-High 11.5 ± 3.6 14.8 ± 3.7
Workload [kg] PLA 1474.1 ± 373.6 1753.2 ± 548.5 Group 0.17
(wt x reps) CrM 1827.0 ± 926.3 2255.0 ± 1121.5 Time 0.001
CrN-Low 1616.5 ± 491.3 1877.3 ± 535.4 Group × Time 0.10
CrN-High 1927.3 ± 830.2 2516.5 ± 867.2
Peak power PLA 425.5 ± 101.1 443.3 ± 107.1 Group 0.10
(W) CrM 452.9 ± 113.7 521.5 ± 119.9 Time 0.001
CrN-Low 440.2 ± 76.0 481.1 ± 88.4 Group × Time 0.57
CrN-High 492.4 ± 95.0 553.3 ± 98.4
Average power PLA 357.7 ± 88.4 382.4 ± 93.2 Group 0.03
(W) CrM 423.8 ± 120.5 456.4 ± 105.0 Time 0.001
CrN-Low 371.6 ± 70.4 396.4 ± 73.4 Group × Time 0.82
CrN-High 451.2 ± 91.8 489.4 ± 89.7
Average velocity PLA 0.50 ± 0.09 0.53 ± 0.11 Group 0.10
(m/s) CrM 0.55 ± 0.09 0.62 ± 0.11 Time 0.001
CrN-Low 0.61 ± 0.83 0.65 ± 0.12 Group × Time 0.74
CrN-High 0.54 ± 0.11 0.61 ± 0.15
Anaerobic sprint performance
Mean power PLA 668.1 ± 172.0 682.7 ± 142.3 Group 0.03
(W) CrM 684.2 ± 129.2 720.5 ± 141.5 Time 0.12
CrN-Low 670.8 ± 124.8 708.9 ± 106.9 Group × Time 0.46
CrN-High 807.9 ± 91.0 797.7 ± 61.4
Peak power PLA 1,464.4 ± 379.7 1,486.8 ± 322.5 Group 0.13
(W) CrM 1,548.4 ± 351.6 1,611.4 ± 440.5 Time 0.11
CrN-Low 1,497.4 ± 270.1 1,565.0 ± 278.1 Group × Time 0.95
CrN-High 1,739.0 ± 275.5 1,783.7 ± 306.8
Total work PLA 6,119.6 ± 991.9 6,423.7 ± 896.4 Group 0.55
(J) CrM 7,188.1 ± 2195.3 6,886.7 ± 744.7 Time 0.76
CrN-Low 6,760.7 ± 1618.4 6,817.5 ± 1290.8 Group × Time 0.71
CrN-High 6,716.3 ± 1532.6 6,884.4 ± 1495.3
Data are mean ± SD
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Fig. 4 Data represent mean ± 95 % CI change in average Tendo™ bench press power (a) and lifting volume based on reps to fatigue during set 3
at 70 % of 1RM bench press (b) following 28 days of supplementation. Statistical notations (p < 0.05 considered significant): (^) denotes
significantly greater than PLA and CrN-Low. (*) denotes significantly greater than PLA
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Fig. 5 Data represent mean ± 95 % CI change in fat free mass (a) and lean body mass (b) following 28 days of supplementation. Statistical
notations (p < 0.05 considered significant): (*) denotes significantly greater than PLA
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observe any between group differences for the same pa-
rameters. Others using beetroot juice as a vehicle for ni-
trate delivery have reported similar findings. For
example, Larsen et al., reported no change in blood pres-
sure following 3-d of ~430 mg nitrate/d [23]. Murphy
and colleagues reported similar findings [25]. To the
contrary, Webb et al., observed a ~10 mmHg decrease
in SBP 2.5 h after ~1,400 mg of nitrate ingestion [31]. In
Study 1 we provided 0.5 g nitrate (CrN-Low) and 1 g
(CrN-High) and found no evidence that CrN reduced
blood pressure or affected HR in comparison to PLA or
CrM. Additionally, no participant had a hypotensive re-
sponse (SBP < 90 mmHg, DBP < 60 mmHg) to either
dose of CrN studied. It is therefore conceivable that a
dose threshold exists for a single dose of nitrate inges-
tion as it pertains to hemodynamic alterations. Based on
our findings, CrN appears to be well tolerated up to 3 g
per serving, yielding 1 g of nitrate, whether ingested
acutely or chronically. Adding to these finding is our ob-
servation of minimal self-reported side effects associated
with acute and chronic CrN ingestion.
During each study we observed a small number of
side effects that were rated as minimal in frequency
and severity. Collectively, the total number of re-
ported side effects was distributed evenly amongst all
treatment groups whereby each treatment group was
no different than the PLA group. These findings are
similar to previous creatine research investigations.
Moreover, creatine supplementation and a diet rich in
nitrates have been shown to have a beneficial influ-
ence on health [4, 34], either of which may explain
the minor, yet positive perturbations of blood lipids
observed in Study 1. It should also be noted that
changes in lipid fractions have been observed previ-
ously accompanying creatine ingestion [9, 26]. There
were no consistent, significant effects on any blood
variable related hepatorenal or muscle enzyme func-
tion. While there were some between group differ-
ences, the pattern for these changes was stochastic
and inconsistent for any treatment group. For ex-
ample, there were significant changes across time for
high-density lipoprotein (HDL), triglyceride (TG), alka-
line phosphatase (ALP), alanine transaminase (ALT),
blood urea nitrogen (BUN), BUN-to-creatinine ratio,
and glucose. Also, CK values for CrN-High (453 – 505
U/L) were elevated above expected normal ranges
(50 – 398 U/L) at baseline and after ingested acutely
[28]. However, similar elevations were not observed
in CK after 28-d of supplements.
The results of the chronic supplementation trial are
intriguing owing to a dichotomy of results suggesting an
improvement in exercise performance unmatched by a
distinct mechanism of action. While we did observed a
significant increase in performance and body composition
characteristics generally favoring the CrM and CrN-High
groups, these results were not associated with a significant
increase in muscle creatine concentrations. In both cases,
CrN-High was significantly greater than the PLA group
and in the latter example, also greater than the CrN-Low.
Despite these differences, only the CrM caused a signifi-
cant increase in muscle creatine at follow-up.
There was no improvement in cycling anaerobic power
output for our assessments despite the CrM group hav-
ing significantly greater creatine stores than CrN-Low,
CrN-High, and PLA groups. It is possible that the dose
of CrM used in Study 2 was too low as compared to
more typical doses of 5 g. This higher dosing pattern
generally yields more consistent results versus studies
using 3 g of CrM [5, 14, 27, 32, 33]. These findings con-
trast claims that there is no need to load when taking
CrN due to greater solubility and retention. The effects
of nitrate as a precursor to nitric oxide may have also
played a role in the development of muscle whereby the
acute effects of nitrates increase exercise performance
directly, while the chronic effects associated with nitrate
supplementation may result from an increase in muscle
protein synthesis [6, 13, 30, 35]. While the former point
has been demonstrated with endurance exercise, the lat-
ter point has recently been hypothesized relative to nitric
oxide’s potential role in protein synthesis and is cur-
rently under investigation by others [6, 30, 35]. There-
fore, it is possible that creatine and nitrate work
synergistically, rather than independently, though the
mechanism of action is currently unknown.
A strength of this research is that we examined CrN at
a supplementation dose that is currently recommended,
as well as at a dose twice that, by first performing a gen-
eral safety assessment, followed by a longer study to
monitor chronic safety parameters and exercise perform-
ance. A limitation this research is that we did not exam-
ine a more typical CrM loading schema using 5 g per
serving. We did, however, give this a great deal of con-
sideration and ultimately decided to examine a dose
equivalent to those used in the highest CrN group. The
decision to use a lower dose partially was based on cer-
tain ingredient manufactures assertions that the in-
creased solubility of CrN would increase intramuscular
creatine concentrations at a lower dose. This apparently
was not the case. However, strength and body compos-
ition changes were similar between the CrN-High and
CrM groups. It is important to understand that study 2
was not a CrM efficacy study, but rather an assessment
of CrN. Future research should examine typically used
creatine dosing and/or CrN-High for longer periods of
time to better understand the mechanisms of action as-
sociated with CrN ingestion. To our knowledge, this is
the first study examining the efficacy of CrN in strength
training individuals. Although Joy et al. [20] have examined
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the safety of CrN up to 2 g, we have extended the current
body of knowledge to 3 g/d, inclusive of a 7-d load-
ing sequence at four times per day. Creatine nitrate
delivered at 3 g was well-tolerated, demonstrated
similar performance benefits to 3 g CrM, in addition,
within the confines of this study, there were no safety
concerns. However, there was no evidence that CrN
at recommended or twice recommended doses is
more efficacious than CrM at the doses studied.
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